Finnish health authorities have decided to resume vaccinations with AstraZeneca, the drug whose use was temporarily suspended last month due to concerns associated with brain clots in people who had received the injection.
To date, 3 rare cases of thrombosis have been reported among Finnish patients, of which one has died.
The Finnish National Advisory Committee on Vaccines (KRAR) has recommended continuing to administer the vaccine to patients over 65 years of age.
The recommendation has been endorsed by the National Institute for Health and Wellness (THL).
Speaking to the national broadcasting company (Yle), the president of KRAR, Ville Peltola, said that what he called "adverse reactions" have been detected in young age groups, but not among those considered "risk groups," in reference to those over 65 years of age.
Endorsed by EMA
Cases of cerebral thrombosis among those vaccinated have been reported in other European countries, including the United Kingdom, Germany and Spain.
The European Medicines Agency (EMA) continues to endorse the use of the British-Swedish vaccine, which it considers safe.
